TARGET

What is TARGET?

TARGET (tumor alterations relevant for genomics-driven therapy) is a database of genes that, when somatically altered in cancer, are directly linked to a clinical action. TARGET genes may be predictive of response or resistance to a therapy, prognostic, and/or diagnostic.

TARGET is intended to be a community resource for translational oncology.  To maintain relevance and keep pace with new preclinical and clinical discoveries, it is updated quarterly.

 

How do I get the TARGET database?

TARGET is available for download as an Excel spreadsheet.

TARGET_db_v2_05042014.xlsx

TARGET_db_v1_07012013.xlsx

 

How can I contribute to the TARGET database?

If you would like to nominate a particular gene for inclusion as being clinically relevant, please complete this survey.

If your submission is selected for inclusion, you will be notified. Furthermore, if you would like to be acknowledged as the expert for that submission, you will be attributed in future editions of TARGET.

 

 

DIAGNOSTIC AND CLINICAL USE PROHIBITED.  THE BROAD INSTITUTE and DFCI MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT or VALIDITY OF ANY INTELLECTUAL PROPERTY RIGHTS OR CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.  In no event shall Broad or DFCI or their Trustees, Directors, Officers, Employees, Students, Affiliates, Core Faculty, Associate Faculty and Contractors, be liable for incidental, punitive, consequential or special damages, including economic damages or injury to persons or property or lost profits, regardless of whether the party was advised, had other reason to know or in fact knew of the possibility of the foregoing, regardless of fault, and regardless of legal theory or basis. You may not download or use any portion of this program for any use not expressly authorized by the Broad. You further agree that the program shall not be used as the basis of a commercial product and that the program shall not be rewritten or otherwise adapted to circumvent the need for obtaining permission for use of the program other than as specified herein.